

**CERTIFICATE OF MAILING**


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, Washington, D.C. 20231

Typed or Printed Name	<b>KIMBERLY ZUEHLKE</b>		
Signature	<i>Kimberly Zuehlke</i>	Date	<b>3 April 2001</b>

**RECEIVED**

APR 11 2001

TECH CENTER 1600/2900


<p style="text-align: center;"><b>TRANSMITTAL FORM</b></p> <p style="text-align: center;"><i>(to be used for all correspondence after initial filing)</i></p> 	Attorney Docket	IRVN-0007CON
	First Named Inventor	Gatanaga et al.
	Application Number	09/712,813
	Filing Date	November 13, 2000
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Title: <i>Factors Affecting Tumor Necrosis Factor Receptor Releasing Enzyme Activity</i>	

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement, 1449 and <u>2</u> references <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 <i>(with copy of Notice to File Missing Parts)</i>	<input type="checkbox"/> Issue Fee Transmittal <i>(with copy of PTOL-85B)</i> <input type="checkbox"/> Formal Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip and Accompanying Petition <input type="checkbox"/> To Convert a Provisional Application <input type="checkbox"/> Power of Attorney <input type="checkbox"/> Revocation <input type="checkbox"/> Associate <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement	<input type="checkbox"/> Request for Refund <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i> <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) <i>(please identify below):</i> <u>Return Postcard</u> _____ _____
--	--	---

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Individual Name	Carol L. Francis	Registration No.	36,513
Firm Name	BOZICEVIC, FIELD & FRANCIS LLP		
Signature	<i>Carol L. Francis</i>		
Date	<i>April 3, 2001</i>		

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	KIMBERLY ZWEHLKE		
Signature	<i>Kimberly Zwehlke</i>	Date	3 April 2001
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>  Address to: Commissioner for Patents Washington, D.C. 20231		Attorney Docket	IRVN-0007CON
		First Named Inventor	Gatanaga et al.
		Application Number	09/712,813
		Filing Date	November 13, 2000
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Title	<i>Factors Affecting Tumor Necrosis Factor Receptor Releasing Enzyme Activity</i>



RECEIVED  
 APR 11 2001  
 TECH CENTER 1600/2900

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

All of the references identified herein were disclosed in parent application Serial No. 09/081,385 and, as such, copies thereof are not included pursuant to the provisions of 37 C.F.R. §1.98(d), except as noted below. References AH and AI have not been cited in the aforementioned parent application; copies of these references are hereby submitted.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefor.

Respectfully submitted,  
 BOZICEVIC, FIELD & FRANCIS LLP

Date: April 3, 2001

By: *Carol L. Francis*  
 Carol L. Francis  
 Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP  
 200 Middlefield Road, Suite 200  
 Menlo Park, CA 94025  
 Telephone: (650) 327-3400  
 Facsimile: (650) 327-3231  
 F:\FORMS\Word 2K forms\IDS - before 1st OA.doc